Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension.
1 Labetalol, an alpha- and beta- adrenoceptor blocking drug, was compared with acebutolol, alone or associated with dihydralazine in forty patients with moderate essential hypertension. 2 Labetalol (400--800 mg daily) seemed to have a slightly higher potency than acebutolol alone (400--800 mg daily). 3 Labetalol (1200--1600 mg daily) had the same potency as the combination of acebutolol (400--800 mg daily) and dihydralazine (50--100 mg daily). 4 Contrarily to acebutolol, the drop in blood pressure with labetalol was not correlated with initial plasma renin activity. 5 Labetalol side effects were minor and did not lead to drug withdrawal.
D000070:Acebutolol / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D004078:Dihydralazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives*; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012083:Renin / Q000097:blood
D004983:Ethanolamines; D006830:Hydralazine; D000070:Acebutolol; D012083:Renin; D004078:Dihydralazine; D007741:Labetalol